Tin tức & Cập nhật

MACE, stroke, death common after acute coronary syndrome in people with bipolar disorder
MACE, stroke, death common after acute coronary syndrome in people with bipolar disorder
25 Jun 2022

In people with bipolar disorder, major adverse cardiovascular events (MACE) are common occurrences after acute coronary syndrome (ACS), a new study has found. Similarly, the risks of all-cause mortality and stroke are also increased post-ACS.

MACE, stroke, death common after acute coronary syndrome in people with bipolar disorder
25 Jun 2022
Tirzepatide: A winning weight-loss therapy for nondiabetic, obese adults
Tirzepatide: A winning weight-loss therapy for nondiabetic, obese adults
25 Jun 2022 bởiRoshini Claire Anthony

Non-diabetic overweight or obese adults experienced a greater reduction in weight and cardiometabolic measures with the addition of tirzepatide to their lifestyle interventions, findings of the SURMOUNT-1 trial showed.

Tirzepatide: A winning weight-loss therapy for nondiabetic, obese adults
25 Jun 2022
PPIs raise death risk in advanced NSCLC patients on antitumour therapy
PPIs raise death risk in advanced NSCLC patients on antitumour therapy
25 Jun 2022
Comorbidities affect immune response to severe COVID-19
Comorbidities affect immune response to severe COVID-19
25 Jun 2022

Immune signatures developed in response to severe COVID-19 appear to vary not only according to the principal disease but also with underlying comorbidities, such as hypertension, diabetes, and heart diseases, a new study has found.

Comorbidities affect immune response to severe COVID-19
25 Jun 2022
Maintenance niraparib a boon in advanced ovarian cancer
Maintenance niraparib a boon in advanced ovarian cancer
24 Jun 2022 bởiJairia Dela Cruz

Use of niraparib in the maintenance setting appears to minimize the risk of progression in advanced ovarian cancer patients, with surgical timing having little to no effect on the drug’s efficacy, as shown in a post hoc analysis of the phase III PRIMA/ENGOT-OV26/GOG-3012 study.

Maintenance niraparib a boon in advanced ovarian cancer
24 Jun 2022